Compare Cardinal Health Inc (CAH) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs DexCom, Inc. — how do they compare? Cardinal Health Inc trades at $231.36 (market cap $54.46B), while DexCom, Inc. trades at $91.21 (market cap $34.26B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Cardinal Health Inc pays a 0.88% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CAH | DXCM | |
|---|---|---|
Market Cap | $54.46B | $34.26B |
Sector | Health | Health |
52-Week High | $240.26 | $91.48 |
52-Week Low | $146.04 | $54.84 |
Enterprise Value | $58.49B | $33.72B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $231.24, down 3.75% on the day, following a strong earnings beat in Q2 2026 with EPS of $2.91 versus $2.42 expected. The stock is in a bullish technical trend with moving averages supporting further upside, while fundamentals show robust revenue growth and improved profitability, with a net income margin of 0.67% for 2025. Recent news highlights record highs post-earnings and optimistic fiscal 2027 guidance.
The outlook for CAH is positive, driven by consistent earnings beats, strong analyst buy ratings (54.55%), and a consensus price target of $270.11 implying significant upside. Key risks include high leverage with a debt-to-asset ratio of 16.09 and reliance on pharmaceutical and specialty business segments for growth amidst competitive pressures.
DXCM trades at $91.48, up 2.18% today, near its 52-week high. The stock shows strong bullish momentum with consistent earnings beats, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to $4.66 billion in 2025, with net income margins improving to 17.93%. Technical indicators signal bullish trends, supported by moving averages, while RSI levels indicate potential overbought conditions. Recent news highlights raised 2026 guidance driven by G7 system adoption and international expansion.
Outlook remains positive due to robust fundamentals and analyst consensus, but risks include premium valuation and competitive pressures. The stock offers growth potential from expanding CGM market share, though investors should monitor margin sustainability and litigation concerns. With 80% buy ratings and a consensus price target of $88.65, near-term upside may be limited, but long-term growth drivers are intact.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
